LHCGR and metabolic syndrome: A more moderate, but at the same time more stable stimulation of steroidogenesis, induced by TP4/2, demonstrates good prospects for its use of TP4/2 and, as one can assume, other LMW allosteric full agonists of LHCGR to compensate for androgen deficiency, both in certain physiological states, including aging, starvation and others, as well as in a number of diseases, which are characterized by an impairment of the hypothalamic–pituitary–gonad axis, including diabetes mellitus and metabolic syndrome.